DEF: Century Therapeutics Seeks Reverse Stock Split Approval

Century Therapeutics, Inc. is calling a Special Meeting of Stockholders on January 22, 2026, to vote on a reverse stock split to maintain its Nasdaq listing.

Summary

• Century Therapeutics, Inc. (Century) is holding a Special Meeting of Stockholders on January 22, 2026, at 9:00 a.m. Eastern Time, virtually.
• The primary purpose is to approve an amendment to the Charter to effect a reverse stock split of outstanding common stock by a ratio of any whole number between 1-for-5 and 1-for-30.
• The Board of Directors will have discretion over the implementation and timing of the reverse stock split, if approved, anytime before June 30, 2026.
• The company received a deficiency letter from Nasdaq on February 26, 2025, for not meeting the $1.00 minimum bid price requirement.
• An extended compliance date to regain Nasdaq listing compliance is February 23, 2026.
• As of November 25, 2025, 87,405,311 shares of common stock were outstanding.
• The reverse stock split will not change the number of authorized shares (300,000,000 common, 10,000,000 preferred) or relative voting power.
• Fractional shares resulting from the split will be paid in cash based on the average closing sales price over five trading days preceding the effective date.
• The Board unanimously recommends a vote FOR the reverse stock split and FOR the adjournment proposal.

Sentiment

Score: 3

Explanation: The filing addresses a critical issue (Nasdaq delisting) with a standard corporate action (reverse stock split). While necessary to maintain listing, the underlying reason (low stock price) is negative. The action itself carries risks and no guarantee of long-term success. The sentiment is slightly negative due to the forced nature of the action and associated risks, despite the proactive approach.

Positives

• The proposed reverse stock split aims to help the company meet Nasdaq's $1.00 minimum bid price requirement, potentially preventing delisting.
• Increasing the stock price could make the common stock more attractive to a broader range of investors, including institutional investors, and improve market perception.
• Maintaining Nasdaq listing helps preserve visibility, liquidity, and value of the common stock, and supports the ability to raise capital and attract industry partners.

Negatives

• The company is currently non-compliant with Nasdaq's $1.00 minimum bid price rule, indicating a low stock price.
• There is no assurance that the reverse stock split will increase the stock price over the long-term or prevent future delisting.
• The reverse stock split may decrease the liquidity of the common stock due to a reduced number of outstanding shares.
• Some stockholders may end up with "odd lots" (less than 100 shares), potentially incurring higher transaction costs.
• The reverse stock split could be viewed negatively by the market, potentially leading to a decrease in overall market capitalization if the price does not increase proportionally.
• The increase in authorized but unissued shares relative to outstanding shares could have an anti-takeover effect, potentially making mergers or changes in control more difficult.

Risks

• Failure to satisfy all Nasdaq listing requirements even after a reverse stock split, leading to potential delisting.
• The reverse stock split may not increase the price of common stock over the long-term or by a multiple of the split ratio.
• Decreased liquidity of common stock due to a reduced number of outstanding shares and potentially fewer market makers.
• Increased transaction costs for stockholders owning odd lots (less than 100 shares) after the split.
• Potential decrease in overall market capitalization if the per-share price does not increase proportionally or maintain its value.
• The relative increase in authorized but unissued shares could be construed as an anti-takeover measure, potentially discouraging mergers or changes in control.

Future Outlook

The company intends to effect a reverse stock split to regain and maintain compliance with Nasdaq's minimum bid price requirement by the Extended Compliance Date of February 23, 2026. The Board believes this action will improve the perception of the common stock and appeal to a broader range of investors, though there is no guarantee of long-term price increase or sustained compliance.

Management Comments

• "We are pleased to invite you to attend a Special Meeting of Stockholders... to approve an amendment to our Second Amended and Restated Certificate of Incorporation... to effect a reverse stock split..." Brent Pfeiffenberger, Pharm.D., President, CEO & Chairman of the Board.
• "The Board believes that the benefits to the Company outweigh the risks and recommends that you vote in favor of granting the Board the discretionary authority to effect the Reverse Stock Split."
• "We believe that effecting the Reverse Stock Split will help us avoid delisting from Nasdaq and any resulting consequences."
• "We believe that the Reverse Stock Split is our best proactive option for demonstrating compliance with the Bid Price Rule prior to the Extended Compliance Deadline..."
• "The Board believes that effecting the Reverse Stock Split is one potential means of increasing the share price of our Common Stock to improve the perception of our Common Stock as a viable investment security."

Industry Context

This filing indicates a common challenge faced by smaller or developing biotechnology companies, which often experience stock price volatility and may fall below exchange minimum bid price requirements. A reverse stock split is a standard corporate action taken to address such compliance issues and maintain listing, which is crucial for investor confidence and access to capital in the highly competitive and capital-intensive biotech industry.

Comparison to Industry Standards

• Many biotechnology companies, particularly those in early clinical stages or with fluctuating R&D results, face challenges in maintaining stock prices above exchange minimums.
• Reverse stock splits are a common strategy employed by companies across various industries, including biotech, to avoid delisting from major exchanges like Nasdaq. For example, companies like Sorrento Therapeutics (SRNE) or Aeterna Zentaris (AEZS) have historically undertaken reverse stock splits to address similar listing compliance issues.
• The proposed ratio range of 1-for-5 to 1-for-30 is typical for companies seeking to significantly boost their per-share price to meet a $1.00 minimum.

Corporate Governance

Stakeholder Impact

• Shareholders: Will own fewer shares but with a proportionally higher per-share price. Those with fractional shares will receive cash. May face higher transaction costs for odd lots. Voting power remains proportionate.
• Employees: Equity awards (options, RSUs) will be adjusted proportionally, maintaining their aggregate value (subject to rounding).
• Potential Investors: A higher stock price may make the company more attractive to institutional investors and brokerage firms, potentially increasing interest and liquidity.
• Industry Partners/Lenders: Maintaining Nasdaq listing helps preserve confidence and the ability to engage in business development or secure financing.

Next Steps

• Stockholders to vote on the reverse stock split and adjournment proposals at the Special Meeting on January 22, 2026.
• If approved, the Board of Directors will determine whether and when to effect the reverse stock split, with a deadline of June 30, 2026.
• If the reverse stock split is implemented, the company will file a Certificate of Amendment with the Delaware Secretary of State.
• The company aims to regain compliance with Nasdaq's $1.00 minimum bid price rule by February 23, 2026.

Key Dates

Recommendation

The proposed reverse stock split is a necessary defensive action to maintain Nasdaq listing, which is crucial for the company's long-term viability, access to capital, and investor perception. While the underlying reason for the split (low stock price) is negative, the proactive measure to avoid delisting is a positive step. However, there's no guarantee the split will lead to sustained price appreciation or improved business fundamentals. Investors should hold to see if the company can leverage its continued listing to improve its operational and financial performance, but new investment based solely on this corporate action is speculative.

Keywords

Century Therapeutics, reverse stock split, Nasdaq listing, stockholder meeting, corporate governance, biotechnology, pharmaceuticals, equity incentive plan, common stock, delisting risk